Summa Equity acquires Sengenics to advance precision medicine through proteomics
Summa Equity Fund II acquires a majority stake in Sengenics, a functional proteomics company with a unique technology for production of full-length, correctly folded and functional proteins. Sengenics leverages its technology to support pharma and academic research in the pursuit of increasing our understanding of proteins within the human body, thereby contributing to advancing precision medicine and healthcare worldwide.14 October 2020, Stockholm, Sweden: Summa Equity , the purpose-driven private equity firm that invests to solve global challenges, has acquired a